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ABSTRACT
Purpose The Thrombolysis in Ischemic Stroke Patients 
(TRISP) collaboration was a concerted effort initiated 
in 2010 with the purpose to address relevant research 
questions about the effectiveness and safety of 
intravenous thrombolysis (IVT). The collaboration also 
aims to prospectively collect data on patients undergoing 
endovascular treatment (EVT) and hence the name of the 
collaboration was changed from TRISP to EVA- TRISP. The 
methodology of the former TRISP registry for patients 
treated with IVT has already been published. This paper 
focuses on describing the EVT part of the registry.
Participants All centres committed to collecting 
predefined variables on consecutive patients prospectively. 
We aim for accuracy and completeness of the data and 
to adapt local databases to investigate novel research 
questions. Herein, we introduce the methodology of a 
recently constructed academic investigator- initiated 
open collaboration EVT registry built as an extension of 
an existing IVT registry in patients with acute ischaemic 
stroke (AIS).
Findings to date Currently, the EVA- TRISP network 
includes 20 stroke centres with considerable expertise 
in EVT and maintenance of high- quality hospital- based 
registries. Following several successful randomised 
controlled trials (RCTs), many important clinical questions 
remain unanswered in the (EVT) field and some of them 
will unlikely be investigated in future RCTs. Prospective 
1undefined Strengths and limitations of this 
study
 ► The EndoVAscular treatment and ThRombolysis for 
Ischemic Stroke Patients (EVA- TRISP) collaboration 
offers a platform to pool individual patient data from 
prospective registries of patients with ischaemic 
stroke undergoing revascularisation therapies.
 ► The large sample size (currently >13 000 endovascular 
treatments (EVTs) from 20 centres), high level of com-
pleteness of data and standardised data ascertainment 
are strengths of EVA- TRISP.
 ► EVA- TRISP will provide data from everyday clinical prac-
tice and address clinically important questions about 
safety and outcomes of patients with ischaemic stroke 
treated with EVT who are not covered by randomised 
controlled trials.
 ► Data are derived from registries that are neither mon-
itored nor randomised. There will be no control group 
without EVT, which disallows the assessment of effec-
tiveness of EVT in study populations.
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registries with high- quality data on EVT- treated patients may help 
answering some of these unanswered issues, especially on safety and 
efficacy of EVT in specific patient subgroups.
Future plans This collaborative effort aims at addressing clinically 
important questions on safety and efficacy of EVT in conditions not 
covered by RCTs. The TRISP registry generated substantial novel data 
supporting stroke physicians in their daily decision making considering 
IVT candidate patients. While providing observational data on EVT in 
daily clinical practice, our future findings may likewise be hypothesis 
generating for future research as well as for quality improvement (on EVT). 
The collaboration welcomes participation of further centres willing to fulfill 
the commitment and the outlined requirements.
INTRODUCTION
Timely recanalisation improves outcomes in patients 
with acute ischaemic stroke (AIS).1 2 Safety and efficacy 
of recanalisation strategies, namely intravenous throm-
bolysis (IVT) and more recently endovascular treatment 
(EVT) (including mechanical thrombectomy with various 
techniques and devices in AIS patients with anterior 
circulation large artery occlusions), have been well docu-
mented in several randomised controlled trials (RCTs).3–9 
A meta- analysis of five RCTs revealed an average 2.5- fold 
reduction in disability through EVT in large vessel occlu-
sions compared with standard care, including IVT.10 
Early recanalisation is currently the cornerstone of acute 
stroke treatment with increasing use globally. This benefit 
is substantially higher with earlier achievement of reca-
nalisation and diminishes with longer onset- to- treatment 
intervals.2 11 12 Previous research has explicitly shown that 
IVT with alteplase within 4.5 hours of symptom onset 
improved AIS patient outcomes.13
Following the results of these RCTs, EVT is recom-
mended as standard of care in patients with intracranial 
large vessel occlusion in several guidelines.14–16 Conse-
quently, health systems all over the world have adapted 
and identify and quickly transfer eligible patients to 
centres offering EVT. Simultaneously, capacity, logistics, 
know- how and 24/7 coverage were developed to cope 
with the quickly increasing demand for this intervention. 
Moreover, two recent RCTs showed benefit with EVT in 
patients treated up to 16 or 24 hours after stroke onset, 
given that presence of a considerable amount of salvage-
able brain tissue had been demonstrated with appropriate 
imaging methods.17 18
Relevant questions in the daily clinical work of treating 
stroke patients suffering from large vessel occlusions 
remain. First, EVT- RCTs included a highly selective patient 
population. This increased the chances to demonstrate 
efficacy and to exclude patients who presumably had a 
low chance for a favourable outcome and patients who 
had a high risk for serious complications. Second, the 
seven published EVT trials3 5–9 19 analysed altogether only 
included 1754 randomised patients (of whom 869 under-
went EVT) with the single smallest trial including only 65 
patients (of whom 33 underwent EVT).8 Usually, after a 
novel treatment is proved effective, a new wave of assump-
tions and extrapolations for treating a broader domain of 
patients begins. As all these excluded patient subgroups 
cannot be studied in future RCTs, in most cases, judge-
ments for treating or not treating with EVT will be based 
on limited knowledge. Some remaining questions will 
eventually be answered with a long delay, but some will 
never be answered in forthcoming RCTs. However, stroke 
physicians keep facing patients where evidence- based 
data do not explicitly contribute to decision making 
for these individuals, in which available treatments may 
very well have a potential benefit as well. Here, prospec-
tive high- quality multicentre registries including large 
numbers of patients representing many subgroups, not 
included or not separately analysed within RCT settings, 
may offer helpful information for basing clinical judge-
ments while being aware that the level of certainty will not 
reach that gained from RCTs. These registries may also 
give strong clues on how trial results are implemented to 
clinical practice and how daily practice safety and efficacy 
levels match with those gained in RCTs. Furthermore, 
registry- based data deliver hints in generating new and 
adequate hypotheses for future RCTs. Another important 
aspect is the recently developing new field of clot prop-
erty research: interested centres can collect detached 
clots and ship them to laboratories where macroscopic 
and microscopic properties of the clot coupled with clin-
ical data can be further investigated and may open new 
avenues in understanding stroke mechanisms. Lastly, 
quality is a central indicator in healthcare, and registry- 
based data can be used in comparisons and for improving 
individual centre acute stroke care pathways. As a prereq-
uisite, such data have to be based on well- maintained 
registries containing a large number of detailed, clearly 
defined and well- characterised variables. The Endovas-
cular Treatment and Thrombolysis for Ischemic Stroke 
Patients (EVA- TRISP) registry aims at meeting these 
prerequisites. Using our decade- long experience from 
the multinational TRISP registry,20 we are now aiming to 
build a prospective multinational registry of AIS patients 
treated with EVT including detailed clinical, laboratory 
and imaging data for future analyses. We are presenting 
herein the current versions of the clinical and imaging 
database items of the EVA- TRISP registry. Additionally, we 
will discuss a selection of specific related topics.
AIMS OF THE EVA-TRISP REGISTRY
The major aim of EVA- TRISP is to address clinically 
important questions about safety and outcomes in 
AIS patients treated with IVT and/or EVT that are not 
covered by RCTs. The idea of EVA- TRISP is that experi-
enced stroke centres with a record and expertise in both: 
(1) usage of IVT and/or EVT and (2) maintenance of 
hospital- based stroke databases pool their data. In addi-
tion to the characteristics of the EVA- TRISP centres stated 
previously, an advantage of EVA- TRISP is the availability 
of more additional variables than in other large- scale 
registries and the commitment by the collaborators to: 
(1) submit accurate and complete data and to (2) be 
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willing to adapt the local databases and quickly add new 
variables retrospectively and prospectively.
COHORT DESCRIPTION
The TRISP collaboration was a concerted effort initiated 
in 2010 by 11 European stroke centres with the purpose 
to address clinically relevant research questions about the 
effectiveness and safety of IVT, and currently, 20 stroke 
centres from nine different countries participate in the 
collaboration (see figure 1 and online supplemental 
appendix 1 for a list of member sites and investigators). 
As the collaboration also aims to prospectively collect 
granular and high- quality data on all consecutive stroke 
patients undergoing EVT, the name is changed from 
TRISP to EVA- TRISP.
EVA- TRISP (former TRISP) operates as an indepen-
dent, non- profit, investigator- driven open platform 
that focuses on generating high- quality data for clinical 
research purposes. The EVA- TRISP research initiatives 
are characterised by informal, project- driven and relaxed 
work processes based on a high level of mutual trust 
and understanding between participating collaborators, 
and no formal scientific leadership committees have so 
far been implemented or deemed necessary. Internal 
communication principally takes place via email and 
teleconferences. The EVA- TRISP collaboration also hosts 
an annual face- to- face meeting during the European 
Stroke Organisation (ESO) conference, and this forum 
is used for overall strategic planning and major deci-
sions. The collaboration welcomes new collaborators 
and project proposals from all stroke centres that fulfil 
the requirements as stated further. The collaboration 
particularly aims at supporting young researchers. Thus, 
with the exception of the very first paper,21 first authors 
of the publications generated by the TRISP invariably 
have been young stroke physicians or PhD students. The 
methodology of the TRISP registry has previously been 
published,20 and currently, data on more than 18 000 IVT- 
treated patients are available in the registry. This paper 
focuses on describing the EVT part of the registry.
The EVA- TRISP registry aims to prospectively collect 
granular and high- quality data on all consecutive AIS 
patients undergoing both IVT and/or EVT. The overall 
purpose is to provide a means to address clinically 
important research questions on the safety and effective-
ness of IVT and/or EVT in AIS patients that are typically 
not covered by RCTs or single- centre research initiatives. 
Furthermore, the EVA- TRISP aims at providing a large 
data source for various stroke care quality improvement 
initiatives. All EVA- TRISP centres have a proven track 
record for delivering high- quality and high- volume 
stroke patient care. Every EVA- TRISP centre offers stroke 
management that fulfils the criteria of stroke centres or 
stroke units as proposed by the ESO.22 The simple idea 
Figure 1 EVA- TRISP centres.
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of the EVT part of the EVA- TRISP registry is that experi-
enced stroke centres with expertise in both EVT imple-
mentation and in the maintenance of hospital- based EVT 
databases pool their data together. An advantage of the 
EVA- TRISP registry is the availability of substantially more 
variables than in other large- scale registries. We strive 
for a commitment by the collaborators to provide data 
of high accuracy and completeness as well as towards 
a willingness among collaborators to swiftly adapt the 
local databases by adding new variables of interest. This 
enables a potential for explorative insights in the puta-
tive prognostic importance of variables with unknown 
influence on outcome or risk of complications, such as 
symptomatic intracranial haemorrhage (sICH). Strengths 
and limitations of the EVA- TRISP registry in general and 
compared with other existing EVT registries are discussed 
further (please see Discussion).
The participating centres have all agreed to fulfil the 
prerequisites that are summarised in box 1. Participa-
tion in other registries does not preclude participation 
in the EVA- TRISP registry. A standard database template 
has been developed by an international expert group 
consisting of stroke physicians and scientists in collabo-
ration with all members, leading to the current standard 
version of the registry (see online supplemental appendix 
2 – registry data elements), which has been agreed on 
by all EVA- TRISP member sites. This comprehensive 
dataset includes over 110 items and covers a wide range 
of data elements, including demographics, prestroke 
health information, acute phase management and long- 
term outcomes including 3 months and 1 year modified 
Rankin Scale (mRS) as well as detailed laboratory data 
and imaging findings. An add- on imaging repository is 
currently under preparation and will be implemented 
within the near future. Electronic medical records used 
at all member sites allow for additional variables to be 
collected quickly and reliably when deemed necessary for 
new projects.
Target population
All AIS patients designated for EVT and in whom inter-
ventionalists gained arterial access are within the target 
population. Therefore, this registry also may include 
patients with misdiagnosis, already recanalised leading to 
premature interruption of the procedure, unsuccessful 
attempts to recanalise and other unforeseeable condi-
tions. Inclusion of patients is not limited to certain EVT 
techniques. The registry will include also patients who 
receive intra- arterial thrombolysis even without mechan-
ical thrombectomy.
Data collection and definitions
Data on the characteristics of patients are collected 
prospectively by all participating centres using stan-
dardised definitions and a standardised form. Not all 
centres have to provide data on all variables but have 
given a commitment to add missing variables retrospec-
tively, if considered relevant to answer a specific research 
question.
The dataset includes patient demographics, history, 
prehospital information, admission data, details on acute 
interventions, stroke unit and/or intensive care informa-
tion, discharge, rehabilitation, outcome data (3 months 
and 1 year outcomes measured by mRS), as well as detailed 
laboratory test results, vital signs and imaging findings 
(see online supplemental appendix 2). Risk factors and 
stroke aetiology will be determined according to standard 
approaches across centres.20
Moreover, neuroimaging findings before and after 
treatment are systematically ascertained and comprise 
imaging modality (CT vs MRI) as well as specific imaging 
findings such as hyperdense artery sign, presence and 
extent of early ischaemic signs, site of vessel occlusion, 
collateral status, presence of tandem occlusion of ipsilat-
eral carotid artery, recanalisation status immediately after 
EVT and on follow- up imaging (quantified according to 
modified treatment in cerebral ischaemia score),23 white 
matter disease severity, presence and burden of cerebral 
microbleeds.
All patients are monitored for occurrence of haemor-
rhagic transformation. Follow- up imaging usually takes 
place close to 24 hours after treatment or earlier in case 
of clinical worsening. Some centres perform follow- up 
imaging only in cases with clinical worsening. The defi-
nition of sICH is in accordance with the definition used 
in the European Cooperative Acute Stroke Study II 
(‘an intracranial hemorrhage was defined as symptom-
atic if the patient had clinical deterioration causing an 
increase in the National Institute of Health Stroke Scale 
Box 1 Universal standards and requirements for the 
databases and centres contributing to the EVA- TRISP 
registry*
 ► Prospective registry of consecutive patients with systematic check- 
up of missing cases.
 ► Comprehensive collection of baseline characteristics according to 
consensus definitions stated in this and the previous methodology 
papers.
Prospective assessment of haemorrhagic complications (symp-
tomatic intracerebral haemorrhage according to the European 
Cooperative Acute Stroke Study (ECASS) ECASS II criteria) and 
functional outcome at 3 and 12 months (according to the modified 
Rankin Scale; either telephone interview, postal questionnaire or 
follow- up visit).
 ► Approval of institutional review board to maintain the respective 
endovascular treatment (EVT) database and to obtain 3- month and 
12- month follow- up data.
 ► EVA- TRISP centres are comprehensive stroke centres with high- 
volume EVT applications – typically university hospitals or closely 
affiliated to university hospitals.
 ► Treatment of acute ischaemic stroke patients with EVT according to 
guidelines valid at the relevant time or documentation of deviation 
therefrom.
*EVA- TRISP welcomes participation and project proposals of further 
centres fulfilling the commitment and the outlined requirements.
 on O









pen: first published as 10.1136/bm





5Nordanstig A, et al. BMJ Open 2021;11:e042211. doi:10.1136/bmjopen-2020-042211
Open access
(NIHSS) score of more than or equal to four points and 
if the hemorrhage was likely to be the cause of the clin-
ical deterioration’).24 The majority of centres additionally 
evaluate type of haemorrhagic transformation (haemor-
rhagic infarction and parenchymal haemorrhage), indi-
cate whether the bleeding occurred remotely from the 
infarcted area and document sICH according to defi-
nitions used in the National Institute of Neurological 
Disorders and Stroke Trial I+II, SITS- MOST and ECASS 
III definitions.25–27 Functional outcomes at 3 months and 
1 year are assessed using the mRS. The mRS is obtained 
by telephone calls, postal/electronical questionnaires or 
outpatient visits. If patients cannot be interviewed, close 
relatives, nurses or family doctors are asked for disability 
status.
We are currently exploring technical, legal and ethical 
as well as financial backgrounds for establishing an elec-
tronic registry to one of the member centres that would 
allow direct data insertion from each centre and holding 
the registry compactly in one single file. Otherwise, each 
centre will maintain their own registry within their own 
electronic system, and data will always be transferred 
without personal identifiers for each single analysis 
looking at one single aspect and leading to one mutual 
international publication. Establishing and maintaining 
such a large database with complete compliance to rules 
and safety measures is a costly procedure and requires 
long- term funding. This option is now under exploration.
Future plans in the registry include the addition of a 
neuroradiology imaging bank that will enable detailed 
image analysis of patients treated with IVT and/or EVT. 
The imaging bank will provide ‘real- world’ diagnostic 
neuroradiology and, used in combination with detailed 
clinical information from the EVA- TRISP registry, anal-
ysis of these imaging data will help to: (1) create stan-
dardised imaging protocols in acute stroke (ie, defining 
optimal threshold for perfusion parameters), (2) identify 
new (ie, a collateral score for the posterior circulation) 
and validate published (ie, different collateral scores for 
the anterior circulation) imaging outcome predictors 
and imaging- based selection tools for reperfusion ther-
apies, (3) assess the generalisability of RCT results to 
subgroups of patients who would have been excluded 
based on imaging criteria (ie, baseline Alberta Stroke 
Program Early CT score (ASPECTS) under five, extracra-
nial vessel pathologies), (4) improve automated analysing 
techniques (ie, machine and deep learning algorithms), 
and (5) enhance the accuracy of outcome prediction 
of different clinical and imaging parameters by imple-
menting new imaging outcomes (e.g. infarct volume, reca-
nalisation status). Neuroimages from TRISP/EVA- TRISP 
patients since 2015 will be pooled centrally. All imaging 
modalities (non- contrast CT, CT angiography, CT perfu-
sion, MRI, MRA, MR perfusion and digital subtraction 
angiography) at baseline and follow- up (up to 3 months 
after stroke onset) will be eligible for analysis. Image anal-
yses will be performed blinded to clinical information 
and treatment decisions and undergo a central systematic 
re- evaluation using a specified case report form including 
all predefined imaging variables.
Stroke- specific image analysing software (ie, OSIRIX 
medical imaging viewer, Quantomo for semiautomated 
volumetric analysis and Rapid Processing of Perfusion 
and Diffusion for perfusion analysis) could be used. 
A detailed case report form for image analysis will be 
designed in review with all collaborators.
Lastly, EVA- TRISP investigators prepared a detailed 
standard operating procedure (SOP) to ascertain that 
all members collecting data are well aware of standard 
interpretations and follow identical steps to avoid unnec-
essary heterogeneities or individual- borne differences. 
The numbers of recruited patients in each participating 
centre during the study period until the end of year 2019 
are reported in table 1 along with the population each 
centre is covering for EVT.
Data elements and completeness
A detailed database is aimed to facilitate the investigation 
of various current and future topics. Data elements are 
listed in detail in online supplemental appendix 2. Over 
time, new data elements may become necessary for new 
individual projects. Should this occur, investigators will 
Table 1 EVA- TRISP centres, time period, number of 
endovascular treatments done and population- base for EVT 
(in alphabetical order)
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quickly supplement the missing variables. Patient age, sex, 
admission NIHSS score, recanalisation status before and 
after thrombectomy and 3 months outcome measured by 
mRS are obligatory data items and must be present for all 
patients (otherwise a patient is not eligible to be included 
to the registry). In general, missing data for any variable 
or patient must not exceed 10%.
Data sources
All paper- based or electronic patient files including labo-
ratory values and imaging data will be used to capture the 
EVA- TRISP registry data points. Based on these different 
sources alongside repeated clinical evaluations under-
taken by the dedicated EVA- TRISP collaborator, registry 
data points that initially remain missing during the early 
stroke treatment process will in the majority of cases be 
possible to reconstruct and thereafter reported to the 
local registry (eg, NIHSS scores). In most cases, the local 
EVA- TRISP investigators form the local stroke team and 
will be actively seeing the patients already in the emer-
gency room and/or at their own stroke units and can 
therefore guarantee completeness of data in most cases.
Quality control
Quality control is another crucial step in multicentre 
large- sized registries since missing data are a frequent 
problem impairing the reliability and generalisability of 
registry- borne data. The EVA- TRISP registry is different 
in this sense because data are not yet directly collected 
to a central registry, but each centre collects their own 
data to their own institutional registry according to a stan-
dard harmonised database item list and SOP. Thus, clear 
variable definitions are easily available for the user when 
data are entered. It is the responsibility of the local EVA- 
TRISP collaborator (usually a senior stroke physician) to 
check and account for the validity and completeness of 
all data points introduced to the local registry. Therefore, 
missing data are expected to be very low. Furthermore, 
all centres have agreed to include all consecutive patients 
attempted with an EVT, and all centres will undertake 
frequent spot checks against internal hospital administra-
tive systems covering EVT procedures as to not leave any 
patient out of the registry. Therefore, our registry data 
will likely include all EVTs performed within a region 
and population, practically equalling to a population- 
based study, although being hospital based, because 
EVT is usually available only at stroke centres serving a 
predefined region and the inhabitant population. Most 
of the required data come from routine procedures that 
are standardly collected and recorded in stroke patient 
care pathways as part of the clinical routine, and there-
fore, these data points are almost always retrievable. In the 
subsequent quality control process, the data files from the 
individual participating centres are merged into a single 
file for further maintenance analyses. Pseudonymised 
individual centre data are sent to the centre leading the 
specific project using encrypted transfer protocols. The 
subsequent data management of the merged database 
will implement checks for missing data along with checks 
for range, consistency and illogical data (eg, NIHSS score 
cannot be minus or over 42 points and can only be full 
points and not decimals; patient age at stroke onset can be 
only in digits and is expected to be from 16 years and very 
rarely over 100 years). Also other procedures regarding 
quality check will be implemented at milestone points, 
such as comparing the performance of data reporting 
among centres.
Registry size and duration
The registry will include all EVT patients from all 
member sites. We anticipate that the absolute numbers 
and proportions of EVT- treated AIS patients will be 
increasing over time and annual inserts will exceed 
thousands shortly. The registry size is not limited. One 
anticipated strength of this registry is the high patient 
number together with detailed information on each 
patient that will allow us to look at many issues that are 
not feasible to investigate within RCTs or even merged 
data from all RCTs because of the fact that they include 
fairly small patient numbers. The use of the registry will 
be launched after 5000 patients’ data have been inserted 
and adequately quality checked. Similarly, this registry 
will be used as long as EVT is a viable option in stroke 
treatment. The unlimited time span requires careful eval-
uation by ethics committees. If the consortium decides 
to end the registry, each centre’s data will be adequately 
returned to the owners, and the registry data will be 
deleted achieving an absolutely non- retrievable condi-
tion according to technical SOPs of the registry- holding 
centre. Thereafter, each individual centre will be free to 
decide how to proceed with their own datasets. Similarly, 
if a centre decides to resign from the registry, their data 
will be adequately returned and will be deleted from the 
main database file after confirmation that the data are 
safely received by the local principal investigator. While 
all patient- related data including clinical, laboratory and 
imaging data are completely anonymised, each centre 
will keep a key file within their local electronic hospital 
system with patient identifiers matching to the patient 
code in the registry (eg, if necessary to go back to patient 
files). This approach is compliant with current principles 
and is the SOP worldwide.
Lead of a single project and authorship principles
The researcher or researchers—usually one or two (rarely 
three)—who originally present the idea and render the 
analysis proposal make(s) the initiation by drafting a stan-
dard 1–2 pages draft stating a clear hypothesis and statis-
tical plan summarising the project (project proposal). 
The proposal is circulated to all member centres and 
discussed for scientific content and feasibility enriched 
with input from a large expert community. After that, the 
enriched plan along with the list of data items required is 
recirculated. If a centre agrees to participate, the centre 
contributes data within the in- advance agreed time 
frame on all consecutive patients with the key variables 
 on O









pen: first published as 10.1136/bm





7Nordanstig A, et al. BMJ Open 2021;11:e042211. doi:10.1136/bmjopen-2020-042211
Open access
of interest. For some projects, retrospective collection of 
data is required. The original proposal makers are enti-
tled to the first and senior authorships. Coauthorships 
are distributed according to contributions. This includes 
mere quantitative means (ie, number of patients contrib-
uted) and quality of data (eg, completeness; considered 
high across EVA- TRISP centres), handling and pooling 
of the multicentre data; maintenance of the pooled data 
set (including data cleaning), statistics, contribution to 
EVA- TRISP in general and intellectual input in details of 
the design or the analyses of the research project; and 
lastly intellectual input to the writing and improving of 
the manuscript. These criteria are suggestions, and the 
researches taking the lead in each project take the final 
responsibility for the fair distribution of authorships.
Each member site possesses its own data, and each 
member site whose data are used is entitled to coauthor-
ship(s). Whenever feasible, an abstract approved by all 
coauthors is submitted to the forthcoming ESO Confer-
ence. All EVA- TRISP member centres and investigators 
are listed at the end of the manuscript as a supplement 
given that the publishing journal’s own format allows this 
approach.
Data ownership, access, use and publications
Each centre is self- financing in data collection and is 
the indisputable owner of their own data. If and when 
a mutual single databank is constructed, each individual 
researcher with the necessary formal training and permis-
sions will be able to insert data directly to the central data-
base on the internet and have access to the researcher’s 
own centre’s data without limitations. Individual scientists 
working on a properly agreed on single project and doing 
data analyses will be granted proper access to all data. In 
case that an individual centre refrains from participating 
in a particular analysis, their data will not be included in 
that analysis. Any publication that is produced from the 
registry data will include authors from each contributing 
centre in accordance to number of patients delivered as 
well as active involvement in analyses and writing work. 
Number of authors and their placement in the author list 
may vary according to the amount of contributions. This 
will be handled openly and in a delicate way aiming at 
mutual consent.
Ethics, informed consent and privacy
Each centre has received necessary official approval from 
their respective local authorities and/or ethical commit-
tees according to their national and local rules (online 
supplemental appendix 3). These permits include 
transfer of data between EVA- TRISP centres. Necessity 
of individual informed consent is dependent on national 
rules and will be collected if necessary. Data are shared 
with respect to the EU law 2016/679 about General Data 
Protection Regulation. In the long run, the aim is to have 
a permanent database residing at a member site. Estab-
lishment and maintenance of the permanent database at 
one centre will be initiated only after a separate ethics 
approval.
DISCUSSION
Endovascular treatment, now fulfilling the criteria for the 
highest level of evidence, has changed acute stroke care 
substantially. Probably approximately 10% of all ischaemic 
stroke patients are eligible for EVT, but the percentages 
may grow as more and more patients are brought to the 
attention of emergency systems, and the treatment indi-
cations will likely expand over time.28 The rapid develop-
ments in acute stroke care put considerable demands on 
healthcare systems and necessitate quick rearrangements 
for coupling these needs. The seven published RCTs and 
following meta- analyses answered most central questions. 
Nevertheless, there are numerous unanswered questions 
remaining in terms of EVT in AIS. Some of these ques-
tions will be solved and satisfied via ongoing and forth-
coming RCTs. Yet, many other issues will never or unlikely 
be tested in RCTs, and stroke physicians need firm data on 
these topics to base their clinical decisions on. Moreover, 
there are certain patient groups where RCTs are ethically 
difficult to organise; an example of this group is patients 
with basilar artery occlusion (BAO). Although a clearly 
important clinical condition that untreated has a poor 
outcome, BAO patients were not included in the large 
EVT trials. An extrapolation from the anterior circulation 
EVT trial results for BAO has currently a strong support 
in clinical practice, and thus EVT is currently offered to 
BAO patients despite limited direct evidence of treatment 
effectiveness. A small multicentre RCT that included 131 
patients—the Chinese Basilar artery occlusion Endovas-
cular intervention versus Standard medical Treatment 
trial29–was prematurely terminated due to slow recruit-
ment and a high cross- over rate that severely hampered 
the interpretability of the intent- to- treat analysis. Another 
RCT with 300 patients included is closed, but data have 
not yet been presented.30 Still, both the per- protocol 
and the as- treated analyses favoured EVT compared 
with best medical treatment. Some small- sized registry 
data showed high recanalisation rates and similar haem-
orrhagic complication rates as in anterior circulation 
patients treated with EVT but more often futile recanali-
sation. Large- scale registry studies may further improve 
our knowledge in this patient group and may help iden-
tify those who will likely benefit or not benefit from EVT 
in a real- life setting.6 31–33 In the absence of RCT- based 
data, comprehensive observational data may be useful 
for individual treatment decisions in clinical practice and 
in evaluating processes of stroke triage and care for IVT 
or EVT. As a prerequisite, such data have to be based on 
well- maintained registries containing large numbers of 
detailed, clearly defined and well- characterised variables. 
The EVA- TRISP registry meets these prerequisites. Ideally, 
the results from such observational studies are verified or 
falsified by RCTs. However, with few exceptions (eg, age 
limit), this is unlikely to happen. Thus, registry- based data 
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will reflect the highest level of evidence in several aspects, 
available currently and in the foreseeable future.
Furthermore, we need to continuously follow- up 
whether the safety and benefit aspects of EVT shown in 
RCTs could be correctly translated to routine clinical 
practice. Indeed, the safety and benefit may be better, 
similar or even worse in daily practice. Registry data can 
easily be compared with RCT data especially when basic 
settings are similar. Additionally, it becomes more and 
more feasible to compare centres, patient subgroups and 
devices. Benchmarking, previously performed by site 
visits, is a popular approach for understanding differ-
ences and making improvements and can now be done 
easily using electronic data.34
Systematically ascertained, comprehensive and high- 
quality observational data are useful to both: (1) chal-
lenge or (2) confirm the clinical usefulness of commonly 
used but often arbitrary eligibility criteria. An early 
example has been the challenge of the usefulness of the 
upper age limit of 80 years for IVT based on comprehen-
sive, observational studies. Eventually, the third Interna-
tional Stroke Trial proved that indeed patients aged 80 
years and older benefit from IVT too.35
Using the TRISP registry, we previously examined the 
safety of IVT in a number of patient subgroups where 
RCT- based data did not exist. Previous publications 
of the TRISP registry: (1) provided insight into safety 
and efficacy of IVT in subgroups of patients who were 
excluded in RCTs (eg, patients dependent on the help 
of others prior to stroke), under- represented or not 
specifically addressed (eg, dissection as cause, impaired 
renal function, low platelet count, body mass index, prior 
use of statins, serotonin uptake inhibitors, prior use of 
novel oral anticoagulants and patients with seizure at 
onset)21 36–45; (2) facilitated the evaluation process of 
acute stroke care such as the meaning of the ‘off- hour- 
thrombolysis’, IVT during ‘working hours’ or the variable 
‘time’ in clinical practice46–48; and (3) served to derive, 
validate and compare risk scores for sICH or functional 
3 months outcome.49–51 These registry- based novel data 
contributed to the numbers of patients treated safely 
and successfully with IVT globally. Ongoing and planned 
research projects within the EVA- TRISP registry collabo-
ration that may fill important knowledge gaps are inves-
tigations on: (I) stroke due to cervical artery dissection, 
(2) stroke with low baseline NIHSS, (3) stroke specifically 
in the anterior cerebral artery (ACA) territory, (4) stroke 
patients with preexisting dependency, (5) significance of 
cerebral collaterals, (6) significance of tandem occlusions 
and (7) stroke patients with active cancer.
Disease- based or intervention- based patient registries 
with consecutive patients recruited in a population- based 
or hospital- based approach are useful in many ways: they 
help describe the natural history, determine clinical effec-
tiveness and cost- effectiveness of healthcare products or 
services, measure or monitor safety and harm, measure 
quality of care, improve quality of care and help with 
benchmarking purposes such as how clinical practices 
vary, what the best predictors of treatment practices are 
and comparing different practices providing a basis for 
further improvements. In such settings, stakeholders 
are several: the primary stakeholder with the EVA- TRISP 
registry is the academic consortium establishing and 
running the registry. Potential stakeholders with such a 
large- scale registry may include public health and regu-
latory authorities, product manufacturers, healthcare 
service providers, payer and commissioning authorities, 
patients and their advocacy groups, treating physician 
groups, academic institutions and professional societies. 
The EVA- TRISP registry aims at including all patients who 
underwent EVT as a treatment for AIS, including patients 
with misdiagnosis, unsuccessful attempts (EVT is defined 
as a puncture to the artery with the aim of recanalisation) 
or other unforeseeable scenarios. In most countries, 
registry- based studies are approved by ethics committees 
with waving informed consent from individual patients 
as demanding informed consent would leave most severe 
patients out of the registry and cause a severe bias on 
representability of any finding.
Imaging has become more and more critical in the 
stroke field. In addition to stroke diagnostics and excluding 
competing aetiologies (eg, stroke mimics), there are a number 
of imaging findings related to increased risk following acute 
treatments (eg, leukoaraiosis52 and microbleeds), or findings 
guiding treatment choices (eg, major artery occlusion reach-
able with a catheter), as well as findings helpful in prognostics 
such as ASPECTS53 or blood Suger, Early ischeamic changes, 
hyperDens artery sign, Age, NIHSS (SEDAN)49 scores. Acute 
stroke patients are increasingly imaged with a package of stan-
dard CT, CT angiography and CT perfusion or in a similar 
fashion with an MRI- based package. These imaging modal-
ities are then analysed quickly for determining diagnosis, 
prognosis and treatment approach. Functional imaging 
modalities are increasingly taken into account for patient 
selection to IVT and EVT instead of strictly deciding according 
to time. The former TRISP registry included few items on 
imaging studies. Imaging requirements were according to 
routine thrombolysis: only a non- contrast CT imaging prior 
to thrombolysis was mandatory. Imaging was not the main 
focus as image analysis is usually labour intensive and not 
always available. Technological improvements may substitute 
some of the expert workforce in image analysis already today 
and in the near future. However, with the developments in 
imaging technologies and increased requirements in patient 
care, currently most patients are imaged with CT angiog-
raphy and CT perfusion in addition to basic non- contract CT 
imaging. Less frequently, patients are imaged with a similar 
versatile package of various MRI sequences. Developments 
in the imaging technology and logistics, decrease in radia-
tion dose used with CT imaging, as well as automatic image 
analysis software development contributed to the prog-
ress. Installing imaging scanners into or adjacent to emer-
gency departments or taking acute stroke suspect patients 
directly to the imaging facility by- passing the emergency 
room has also improved the availability of more detailed 
imaging. Patient selection for the best individual treatment 
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is becoming increasingly dependent on neuroimaging with 
the goal of providing rapid patient- specific metrics such as 
tissue viability, vessel patency status, thrombus characteristics 
and cerebral perfusion, etc. Imaging findings have also been 
used for patient selection in some highly successful IVT and 
EVT RCTs.4 5 54–56 Detailed imaging information is even more 
crucial when EVT is considered. Therefore, the establishing 
of an imaging repository parallel with the EVA- TRISP registry 
received a widespread support from members. To date, the 
choice of imaging modalities, parameters and thresholds 
varies widely across medical centres. No standardised imaging 
protocols currently exist, other than joint statements from 
professional societies.57 A large, multicentre neuroimaging 
registry with state- of- the- art re- evaluation of images combined 
with detailed clinical data of IVT/EVT- treated stroke patients 
would be helpful for validating between modalities, defining 
thresholds, enhancing automated assessments and creating 
standards in neuroimaging for AIS. For the imaging part 
of the database, we will collect baseline, interventional and 
follow- up images (up to 3 months after stroke onset) from all 
stroke patients included in TRISP since 2012. All images will 
be centrally analysed using a predefined, standardised form.
Strengths and limitations of the EVA-TRISP registry
Strengths of EVA- TRISP registry include: (1) the high 
completeness level of data with few missing data, (2) large 
sample sizes that reduce the risk of bias and allows adjust-
ments for confounders, (3) the systematic and standardised 
data ascertainment that increases the homogeneity of the 
study population, (4) the intrinsic motivation of the study 
personnel that leads to a high rate of completeness of ascer-
tained data sets, contributing to a high- quality registry and 
(5) the dynamic nature of the EVA- TRISP database due to the 
commitment of the centres to adapt the local database and 
add variables retrospectively and prospectively. In addition, 
(6) a large number of variables is gathered including those 
with unknown prognostic importance. This allows addressing 
novel yet unidentified research questions. Moreover, (7) 
pooling of individual patient data increases generalisability 
compared with single centre studies, and (8) the fact that 
variables and outcomes have been collected irrespective of 
the present research question, reduces the risk of a bias. (9) 
As most EVA- TRISP centres are regional reference centres 
for acute patient care, particularly for EVT, the EVA- TRISP 
registry will resemble a population- based registry. Limitations 
are inherent to the design of EVA- TRISP: (1) Data are derived 
from registries that are neither monitored nor randomised. 
Usually, there will be no control group without EVT that 
disallows the assessment of effectiveness of EVT in study 
populations. (2) As true for all observational studies, anal-
yses based on registers have a higher risk of bias than RCTs. 
Thus, we urge to a cautious interpretation of findings and 
observations. (3) All EVA- TRISP centres are experienced in 
stroke treatment. This expertise implies—as a downside—a 
limited generalisability of findings to all stroke providers with 
less expertise and less advanced settings. (4) The majority of 
our included patients are Caucasians and from high- income 
countries. Thus, we cannot compare ethnical differences, nor 
can we compare health systems with various funding levels. 
(5) Currently, there is no ‘core lab’ to validate haemorrhagic 
complications and 3- month mRS ratings. As valid for other 
major registries like SITS and GWTG, local interpretation 
of outcome data may differ between sites. Since EVA- TRISP 
centres are mostly high- volume centres with long- standing 
experience in maintaining IVT databases, this bias is likely to 
be smaller than in most of the other registries.
SUMMARY
The EVA- TRISP collaboration is an open platform dedi-
cated to conduct joint research projects in AIS patients 
treated with IVT and/or EVT. The aims of the EVA- TRISP 
collaboration are to increase knowledge on the safety and 
efficacy of IVT and EVT, study outcomes after IVT and 
EVT, to evaluate processes of acute stroke care as well as 
to document and improve acute stroke care quality. Our 
previous achievements prove that this collaboration has 
the potential to provide versatile observational informa-
tion on treatment of AIS patients during daily clinical 
practice. Prospective and standardised documentation 
of individual patient data according to consensus defini-
tions is a major requirement to maintain the quality of the 
EVA- TRISP registry. Publishing this methodology paper 
improves the transparency of the registry and collected 
data. EVA- TRISP welcomes participation and project 
proposals of further centres fulfilling the requirements 
stated previously.
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